Abstract
We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Current Vascular Pharmacology
Title:Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Volume: 14 Issue: 4
Author(s): Mohammed Fakhry, Khalid Al-Rasadi, Khamis Al-Hashmi, Khalid Al-Waili, Raul D. Santos, Haitham Amin, Fahad O.A.S. Baslaib, Omar Al-Hallaq, Obaid Al-Jassim, Afzal H. Yusufali, Abdel R. Medani, Hossam Elghetany, Ibrahim Al-Zakwani, Akram Al-Khadra, Othman Metwally, Khalid Al-Nemer, Faisal Al-Anazi, Shorook Al-Herz, Mahmoud Al-Awadhi, Omer Al-Tamimi, Abdullah Shehab, Ali T. Al-Hinai, Mohamed Arafah and Wael Al-Mahmeed
Affiliation:
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Abstract: We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Export Options
About this article
Cite this article as:
Fakhry Mohammed, Al-Rasadi Khalid, Al-Hashmi Khamis, Al-Waili Khalid, Santos D. Raul, Amin Haitham, Baslaib O.A.S. Fahad, Al-Hallaq Omar, Al-Jassim Obaid, Yusufali H. Afzal, Medani R. Abdel, Elghetany Hossam, Al-Zakwani Ibrahim, Al-Khadra Akram, Metwally Othman, Al-Nemer Khalid, Al-Anazi Faisal, Al-Herz Shorook, Al-Awadhi Mahmoud, Al-Tamimi Omer, Shehab Abdullah, Al-Hinai T. Ali, Arafah Mohamed and Al-Mahmeed Wael, Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161113666151026115921
DOI https://dx.doi.org/10.2174/1570161113666151026115921 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Factors Affecting 30-Day Mortality in Chinese Patients with Acute Myocardial Infarction: A Registry-Based Cohort Study
Vascular Disease Prevention (Discontinued) ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease
Current Drug Targets Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana
Current HIV Research Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Current Vascular Pharmacology Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Evaluation of Post-Surgical Cognitive Function and Protein Fingerprints in the Cerebro-Spinal Fluid Utilizing Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass-Spectrometry (SELDI-TOF MS) After Coronary Artery Bypass Grafting: Review of Proteomic Analytic Tools and Introducing a New Syndrome
Current Medicinal Chemistry β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure
Current Vascular Pharmacology The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Breastfeeding and Diabetes
Current Diabetes Reviews The Rabbit as an Experimental and Production Animal: From Genomics to Proteomics
Current Protein & Peptide Science Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology